1-4 of 4
Isabelle Vande Broek, MD, PhD
Close
Save search
Sort by
Journal Articles

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Free
Inge Oudaert, MSc, Sylvia Faict, MSc, Ludovic D'Auria, PhD, Jonas Dehairs, PhD, Ken Maes, Philip Vlummens, MD, Lotte Jacobs, BSc, Kim De Veirman, Elke De Bruyne, PhD, Karel Fostier, MD, Isabelle Vande Broek, MD PhD, Rik Schots, Karin Vanderkerken, PhD, Johannes V. Swinnen, PhD, Eline Menu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3058.
https://doi.org/10.1182/blood-2019-122857
Published: 2019
Journal Articles

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Free
Maximilian Merz, Isabelle Vande Broek, MD PhD, Manuel Pérez, Dr., Brigitte Kolb, MD, Argiris Symeonidis, MD PhD, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, BS, MBA, Hartmut Goldschmidt
Journal: Blood
Blood (2019) 134 (Supplement_1): 3115.
https://doi.org/10.1182/blood-2019-122706
Published: 2019
Journal Articles

Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma

Free
Charalampia Kyriakou, MD PhD, Philip Murphy, MD, Maria Teresa Petrucci, MD, Pamela Bacon, Philip Lewis, Hélène Gilet, MSc, Benoit Arnould, PhD, Isabelle Vande Broek, MD PhD, Xavier Leleu, MD
Journal: Blood
Blood (2015) 126 (23): 2085.
https://doi.org/10.1182/blood.V126.23.2085.2085
Published: 2015
Journal Articles

Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma.

Free
Isabelle Vande Broek, MD, PhD, Xavier Leleu, Dan Duda, MD, PhD, Benjamin Van Camp, MD, PhD, Karin Vanderkerken, Ivan van Riet, PhD
Journal: Blood
Blood (2009) 114 (22): 2807.
https://doi.org/10.1182/blood.V114.22.2807.2807
Published: 2009